These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 17375046)

  • 1. Vascular disrupting agents in clinical development.
    Hinnen P; Eskens FA
    Br J Cancer; 2007 Apr; 96(8):1159-65. PubMed ID: 17375046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
    Cai YC; Zou Y; Xian LJ
    Yao Xue Xue Bao; 2010 Mar; 45(3):283-8. PubMed ID: 21351502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of vascular disrupting agents and ionizing radiation.
    Clémenson C; Chargari C; Deutsch E
    Crit Rev Oncol Hematol; 2013 May; 86(2):143-60. PubMed ID: 23177097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
    McKeage MJ; Baguley BC
    Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P; Rossi E; Castaldo V; Sacco PC; Colantuoni G
    Oncologist; 2009 Jun; 14(6):612-20. PubMed ID: 19474164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular disrupting agents: a new class of drug in cancer therapy.
    Gaya AM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.
    Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG
    Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
    Horsman MR; Bohn AB; Busk M
    Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
    Cai SX
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):79-101. PubMed ID: 18221055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular disrupting agents.
    Lippert JW
    Bioorg Med Chem; 2007 Jan; 15(2):605-15. PubMed ID: 17070061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New vascular disrupting agents in upper gastrointestinal malignancies.
    Quatrale AE; Porcelli L; Gnoni A; Numico G; Paradiso A; Azzariti A
    Curr Med Chem; 2014; 21(8):1039-49. PubMed ID: 23992324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taking down tumors: vascular disrupting agents entering clinical trials.
    O'Hanlon LH
    J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
    [No Abstract]   [Full Text] [Related]  

  • 15. Vascular damaging agents.
    Patterson DM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
    Head M; Jameson MB
    Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour vascular disrupting agents: combating treatment resistance.
    Tozer GM; Kanthou C; Lewis G; Prise VE; Vojnovic B; Hill SA
    Br J Radiol; 2008 Oct; 81 Spec No 1():S12-20. PubMed ID: 18819993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in vascular disrupting agents in cancer therapy.
    Porcù E; Bortolozzi R; Basso G; Viola G
    Future Med Chem; 2014 Sep; 6(13):1485-98. PubMed ID: 25365233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
    Kanthou C; Tozer GM
    Int J Exp Pathol; 2009 Jun; 90(3):284-94. PubMed ID: 19563611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?
    Raben D; Ryan A
    Clin Lung Cancer; 2005 Nov; 7(3):175-9. PubMed ID: 16354311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.